Sg3 Management, LLC Sarepta Therapeutics, Inc. Call Options Transaction History

Sg3 Management, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	SELL	$62.69 - $88.44 $3.45 Million - $4.86 Million	-55,000 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$63.15 - $90.42 $4.16 Million - $5.95 Million	-65,800 Reduced 54.47%	55,000 $4.3 Million
Q4 2021 Feb 15, 2022	BUY	$77.28 - $99.42 $7.57 Million - $9.74 Million	98,000 Added 429.82%	120,800 $10.9 Million
Q3 2021 Nov 15, 2021	SELL	$65.97 - $92.48 $474,984 - $665,856	-7,200 Reduced 24.0%	22,800 $2.11 Million
Q2 2021 Aug 16, 2021	BUY	$69.38 - $86.75 $797,870 - $997,625	11,500 Added 62.16%	30,000 $2.33 Million
Q4 2020 Feb 16, 2021	BUY	$125.56 - $178.74 $125,560 - $178,740	1,000 Added 5.71%	18,500 $3.15 Million
Q3 2020 Nov 13, 2020	BUY	$127.12 - $172.34 $2.22 Million - $3.02 Million	17,500 New	17,500 $2.46 Million

530

84.5M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $12.1B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Sg3 Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg3 Management, LLC with notifications on news.